시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 CTLA4(Cytotoxic T-Lymphocyte-Associated Protein 4) 저해제 시장 보고서(2025년)
Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Inhibitors Global Market Report 2025
상품코드 : 1720775
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,342,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,167,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,992,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

CTLA4 저해제 시장 규모는 향후 수년간 급성장할 것으로 예측됩니다. 2029년에는 CAGR 14.7%로 성장할 전망이며, 207억 7,000만 달러로 성장이 예측됩니다. 예측 기간 동안 성장의 배경에는 병용 요법에 대한 수요 증가, 암 이환율 상승, 신흥국 시장에서 채용 확대, 진행 중인 임상시험 및 파이프라인 개발, 면역 요법에 대한 규제 당국의 지원, 표적 치료에 대한 환자 접근성 개선, 전략적 제휴 및 인수 등이 있습니다. 이 기간에 예상되는 주요 동향으로는 차세대 CTLA-4 저해제, 이중특이성 항체, 병용 면역요법, 개별화 암백신, AI를 활용한 창약, 환자 선택을 위한 바이오마커, 모노클로날 항체공학의 진보, 표적 약물 전달 시스템, 혁신적인 임상시험 디자인 및 치료 최적화를 위한 실데이터 통합 등이 있습니다.

종양학 연구 개발에 대한 투자 증가는 CTLA4 저해제 시장의 확대를 촉진할 것으로 예측됩니다. 종양학 연구비의 증가는, 세계 암 부담의 증가, 면역 요법 및 표적 치료 진보, 환자의 생존과 QOL을 향상시키는 혁신적 치료에 대한 강한 수요에 의해서 촉진되고 있습니다. 투자 증가는 신규 치료법 발견을 가속화하고 암에 대한 면역관문 치료 강화에 초점을 맞춘 임상시험을 개선합니다. 예를 들면, 2023년 5월, 미국 방사선종양학회(ASTRO)는, 미국 국립 암 연구소(NCI)가 2024년의 암 연구 자금으로서 99억 8,800만 달러를 요구해, 2023년에 할당된 73억 달러에서 27억 달러 증가한 것을 보고했습니다. 그 결과 암 연구개발 투자 증가가 CTLA-4 저해제 시장 성장에 기여하고 있습니다.

CTLA-4 저해제 시장의 주요 기업은 신약 제제 평가, 투여 요법 최적화, 암 환자의 치료 반응 개선을 위한 임상시험을 실시했습니다. 이러한 임상시험은 CTLA-4 저해제와 다른 면역요법과의 병용 가능성을 탐색하는 것으로, 멜라노마 이외에도 적용을 확대해 다양한 암종에서 전 생존율을 향상시키는 것을 목표로 하고 있습니다. 2024년 12월, 중국의 바이오의약품 회사인 Akeso Inc.는 프로그램 세포사 리간드 1(PD-L1) 저해제에 의한 전 치료 후 진행한 진행성 또는 전이성 비소세포폐암(NSCLC) 환자에 대한 병용 요법인 카도닐리맙의 제Ib/II상 임상시험(AK104-IIT-018)을 발표했습니다. 카도닐리맙은 프로그램 세포사단백질1(PD-1)과 CTLA-4 면역 체크포인트를 표적으로 하는 이중특이성 항체로 면역억제를 저해하면서 동시에 T세포의 활성화 및 종양에 대한 면역반응을 증강합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향 및 전략

제4장 시장-거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석 및 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도 및 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹 및 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문 및 전략

제36장 부록

AJY
영문 목차

영문목차

Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors are a class of immunotherapy drugs that block the CTLA-4 protein on T cells, enhancing the immune system's ability to target and destroy cancer cells. By inhibiting CTLA-4, these drugs prevent the downregulation of immune responses, sustaining T-cell activation and improving cancer treatment efficacy. They can be used alone or in combination with other immune checkpoint inhibitors to strengthen anti-tumor responses and enhance patient outcomes across various cancers.

The primary types of CTLA-4 inhibitors include monotherapy and combination therapy. Monotherapy involves using a single drug, such as a CTLA-4 inhibitor, to treat cancer. These inhibitors are applied in treating melanoma, renal cell carcinoma, colorectal cancer, and other cancers. They are distributed through multiple channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors market research report is one of a series of new reports from The Business Research Company that provides cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors market statistics, including cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors industry global market size, regional shares, competitors with a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors market share, detailed cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors industry. This cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) market size has grown rapidly in recent years. It will grow from $10.43 billion in 2024 to $11.99 billion in 2025 at a compound annual growth rate (CAGR) of 15.0%. The growth during the historic period was driven by the rising prevalence of cancer, increasing clinical trials, greater adoption of checkpoint inhibitors, advancements in healthcare infrastructure, rising investments in oncology research, the expansion of combination therapies, growing awareness of immune-oncology treatments, and pharmaceutical collaborations.

The cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) market size is expected to see rapid growth in the next few years. It will grow to $20.77 billion in 2029 at a compound annual growth rate (CAGR) of 14.7%. The projected growth in the forecast period can be attributed to the increasing demand for combination therapies, a rising incidence of cancer, greater adoption in emerging markets, ongoing clinical trials and pipeline developments, regulatory support for immunotherapies, improved patient access to targeted treatments, and strategic partnerships and acquisitions. Key trends expected in this period include next-generation CTLA-4 inhibitors, bispecific antibodies, combination immunotherapies, personalized cancer vaccines, AI-driven drug discovery, biomarkers for patient selection, advancements in monoclonal antibody engineering, targeted drug delivery systems, innovative clinical trial designs, and the integration of real-world data for treatment optimization.

The increasing investment in oncology research and development is expected to drive the expansion of the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors market. The rise in oncology research funding is fueled by the growing global cancer burden, advancements in immunotherapy and targeted treatments, and the strong demand for innovative therapies that enhance patient survival and quality of life. Increased investment accelerates the discovery of novel therapies and improves clinical trials focused on enhancing immune checkpoint treatments for cancer. For example, in May 2023, the American Society for Radiation Oncology (ASTRO) reported that the National Cancer Institute (NCI) requested $9.988 billion in cancer research funding for 2024, representing a $2.7 billion increase from the $7.3 billion allocated in 2023. As a result, the rising investment in oncology research and development is contributing to the growth of the CTLA-4 inhibitors market.

Leading companies in the CTLA-4 inhibitors market are conducting clinical trials to evaluate new drug formulations, optimize dosage regimens, and improve treatment responses in cancer patients. These trials explore the potential of CTLA-4 inhibitors in combination with other immunotherapies, aiming to expand their applications beyond melanoma and enhance overall survival rates across various cancer types. In December 2024, Akeso Inc., a China-based biopharmaceutical company, announced the phase Ib/II clinical study (AK104-IIT-018) of cadonilimab, a combination therapy for patients with advanced or metastatic non-small cell lung cancer (NSCLC) who had progressed after prior programmed cell death ligand 1 (PD-L1) inhibitor treatment. Cadonilimab is a bispecific antibody targeting programmed cell death protein 1 (PD-1) and CTLA-4 immune checkpoints, simultaneously enhancing T-cell activation and immune response against tumors while reducing immune suppression.

In March 2023, BioNTech SE, a Germany-based biotechnology company, partnered with OncoC4 Inc. to develop and commercialize OncoC4's next-generation anti-CTLA-4 monoclonal antibody candidate, ONC-392. This collaboration focuses on advancing ONC-392 as both a monotherapy and in combination with anti-PD-(L)-1 antibodies for treating various solid tumors. Under the agreement, both companies will jointly oversee the clinical development of ONC-392 and share development costs equally. OncoC4 Inc. is a US-based biopharmaceutical company specializing in the development of next-generation anti-CTLA-4 monoclonal antibodies.

Major players in the cytotoxic t-lymphocyte-associated protein 4 (ctla-4) inhibitors market are Pfizer Inc., Merck & Co. Inc., Bristol Myers Squibb, AstraZeneca plc, Novartis AG, GSK plc, Eli Lilly and Company, BioNTech SE, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Shanghai Fosun Pharmaceutical (Group) Co. Ltd., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Incyte Corporation, Ono Pharmaceutical Co. Ltd., Bio-Techne Corporation, Innovent Biologics Inc., Akeso Inc., Shanghai Junshi Biosciences Co. Ltd., Xencor, Agenus Inc., Harbour BioMed, Molecular Templates Inc., BioAtla Inc., OncoC4 Inc., and Xilio Therapeutics Inc.

North America was the largest region in the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors market consists of sales of ipilimumab and tremelimumab. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Inhibitors Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cytotoxic t-lymphocyte-associated protein 4 (ctla-4) inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for cytotoxic t-lymphocyte-associated protein 4 (ctla-4) inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cytotoxic t-lymphocyte-associated protein 4 (ctla-4) inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Inhibitors Market Characteristics

3. Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Inhibitors Market Trends And Strategies

4. Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Inhibitors Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Inhibitors Growth Analysis And Strategic Analysis Framework

6. Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Inhibitors Market Segmentation

7. Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Inhibitors Market Regional And Country Analysis

8. Asia-Pacific Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Inhibitors Market

9. China Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Inhibitors Market

10. India Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Inhibitors Market

11. Japan Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Inhibitors Market

12. Australia Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Inhibitors Market

13. Indonesia Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Inhibitors Market

14. South Korea Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Inhibitors Market

15. Western Europe Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Inhibitors Market

16. UK Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Inhibitors Market

17. Germany Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Inhibitors Market

18. France Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Inhibitors Market

19. Italy Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Inhibitors Market

20. Spain Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Inhibitors Market

21. Eastern Europe Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Inhibitors Market

22. Russia Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Inhibitors Market

23. North America Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Inhibitors Market

24. USA Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Inhibitors Market

25. Canada Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Inhibitors Market

26. South America Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Inhibitors Market

27. Brazil Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Inhibitors Market

28. Middle East Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Inhibitors Market

29. Africa Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Inhibitors Market

30. Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Inhibitors Market Competitive Landscape And Company Profiles

31. Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Inhibitors Market Other Major And Innovative Companies

32. Global Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Inhibitors Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Inhibitors Market

34. Recent Developments In The Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Inhibitors Market

35. Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Inhibitors Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기